服用胺碘酮,这8点一定要注意!

2021-12-20 袁雪晴 章丽 哈特瑞姆心脏科普

胺碘酮不是谁想用就能用的!

胺碘酮是20世纪60年代为抗心绞痛而合成并检测的药物,但人们后来发现其具有抗心律失常作用,成为心内科常用药。

但是长期口服胺碘酮的不良反应发生率相对较高,而很多不良反应是由于由长期治疗的药物组织蓄积导致,因此,进行基线检测(也就是服药之前先做一次检查)和定期监测(服药之后定期复查)非常重要。

一、咳嗽、气短及时就诊;复查胸片

长期使用胺碘酮会引起肺部不良反应,其与总累积剂量的关系密切,因此,肺部毒性一般要在胺碘酮治疗开始数月至数年后才会发生;也有在治疗2-3周内发生严重肺部毒性的病例,但相对少见。临床可表现为慢性间质性肺炎,肺间质纤维化。

因此,口服胺碘酮的患者应警惕肺部病变:

治疗开始前检查胸片作为基线参考;

之后无症状患者应每3-6月复查一次胸片;

有咳嗽、气短等相关症状的患者需及时到医院诊治。

二、每3~6个月复查甲状腺功能

有报道显示使用较高剂量的胺碘酮的患者发生甲亢或甲减的风险约20%,剂量较低时的风险也较低,约3%-4%。因此:

开始胺碘酮治疗前患者应接受甲状腺功能检测;

开始胺碘酮治疗后每3-6个月复查一次甲状腺功能,如有异常应停用或换用其他抗心律失常药物。

三、每3~6月复查心电图

胺碘酮可以引起心动过缓和房室结传导阻滞,QT间期延长。但胺碘酮的致心律失常发生率比其他类抗心律失常药物更低。因此:

口服胺碘酮前应进行心电图检查;

之后应每3-6月复查一次心电图。

四、每3~6个月复查肝功能

胺碘酮可以引起肝功能异常,因此口服胺碘酮后应每3-6月复查肝功能,若血清转氨酶水平是基线的2倍以上,考虑诊断为肝炎,大多数患者应停用胺碘酮。

五、畏光、视物模糊要查眼

接受长期胺碘酮治疗的患者会出现角膜微沉着等不良反应;患者如果在用药期间出现畏光和视物模糊等症状,应立即进行眼部复查。在服用胺碘酮期间若无症状,则不需要该检查。

六、餐中服药,减少胃肠道不良反应

胺碘酮引起的胃肠道不良反应大多发生于初始负荷治疗阶段,包括恶心、呕吐、厌食、腹泻和便秘。餐中服药(就是饭吃到一半,把药吃了,再继续吃饭)或降低剂量可减少胃肠道副作用。

七、手抖、走路不稳需就诊

胺碘酮引起的神经毒性包括震颤(典型如大家熟知的帕金森病手抖症状)、共济失调(如走路不稳)、周围神经病伴感觉异常(如触觉、味觉异常),以及睡眠障碍等。出现神经症状的患者应及时停用胺碘酮。

八、不可自行停用药物

最后强调一下:

所谓的停用胺碘酮不是自行停用,而是要经医生诊断,症状确与药物有关后,评估风险获益更改治疗方案,在医生指导下停用.如服药期间出现上述症状,可直接心内科就诊,尽快寻求专科医生指导。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1083448, encodeId=61b5108344865, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Thu Dec 23 08:29:32 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297762, encodeId=c714129e762d6, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 22 05:21:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082219, encodeId=75761082219d9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1ce2565171, createdName=1256fb1bm59暂无昵称, createdTime=Mon Dec 20 20:53:17 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082126, encodeId=0d60108212690, content=谢谢分享,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96425723286, createdName=ms5000000353966274, createdTime=Mon Dec 20 16:16:16 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2021-12-23 ms3000000884115523

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1083448, encodeId=61b5108344865, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Thu Dec 23 08:29:32 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297762, encodeId=c714129e762d6, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 22 05:21:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082219, encodeId=75761082219d9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1ce2565171, createdName=1256fb1bm59暂无昵称, createdTime=Mon Dec 20 20:53:17 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082126, encodeId=0d60108212690, content=谢谢分享,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96425723286, createdName=ms5000000353966274, createdTime=Mon Dec 20 16:16:16 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1083448, encodeId=61b5108344865, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Thu Dec 23 08:29:32 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297762, encodeId=c714129e762d6, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 22 05:21:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082219, encodeId=75761082219d9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1ce2565171, createdName=1256fb1bm59暂无昵称, createdTime=Mon Dec 20 20:53:17 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082126, encodeId=0d60108212690, content=谢谢分享,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96425723286, createdName=ms5000000353966274, createdTime=Mon Dec 20 16:16:16 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2021-12-20 1256fb1bm59暂无昵称

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1083448, encodeId=61b5108344865, content=感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8f15574968, createdName=ms3000000884115523, createdTime=Thu Dec 23 08:29:32 CST 2021, time=2021-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297762, encodeId=c714129e762d6, content=<a href='/topic/show?id=f6a484255be' target=_blank style='color:#2F92EE;'>#胺碘酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84255, encryptionId=f6a484255be, topicName=胺碘酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Dec 22 05:21:41 CST 2021, time=2021-12-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082219, encodeId=75761082219d9, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a1ce2565171, createdName=1256fb1bm59暂无昵称, createdTime=Mon Dec 20 20:53:17 CST 2021, time=2021-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1082126, encodeId=0d60108212690, content=谢谢分享,感谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=96425723286, createdName=ms5000000353966274, createdTime=Mon Dec 20 16:16:16 CST 2021, time=2021-12-20, status=1, ipAttribution=)]
    2021-12-20 ms5000000353966274

    谢谢分享,感谢

    0

相关资讯

当心!“万能药”胺碘酮,也会出现严重后果!

由于作用机制广泛,胺碘酮对各种快速心律失常都有较好的治疗效果,在各种指南中都有它的身影

胺碘酮规范应用专家建议

胺碘酮是临床常用抗心律失常药。随着心律失常治疗理念的不断更新,胺碘酮的临床地位在不断变化。临床实践中也有诸多不规范应用的情况。本专家建议从适应证、药理学与临床、使用剂量、随访和副作用等方面介绍了胺碘酮,重在规范应用。同时对一些有争议的问题也表达了专家组的观点。 

NEJM:胺碘酮引起的皮肤变色-病例报道

皮肤变色是胺碘酮罕见的不良反应,可能会随着药物的停用而减轻。跌倒可归因于体位性低血压。在住院期间,对患者的药物进行了调整,包括停用胺碘酮。

Circulation:静脉或骨内给药对院外心脏骤停患者预后的影响

抗心律失常药物还没有被证明能显著提高由休克难治性心室颤动/无脉性室性心动过速引起的院外心脏骤停的总生存率。而且给药途径如何影响这一点也尚不清楚。在一项随机化、安慰剂为对照的临床试验的判断分析中,研究人员对比了在ALPS试验中由急救医疗人员随机分配抗心律失常药物vs安慰剂的休克难治性室颤/无脉性室速患者的生存期和出院期的差异,并根据静脉和骨内给药分层。共3019位被随机分配的患者,2358例经静脉通

氢氯噻嗪、胺碘酮、环丙沙星、萘普生等可引发光敏性反应,造成皮肤损伤

晒晒太阳是好事,但有时候就会发生严重晒伤,皮肤出现灼热和瘙痒感、发红、肿胀及起疱等。这里值得注意的是,也许是因为服用的某种药物让你对阳光更敏感。